These are top 10 stocks traded on the Robinhood UK platform in July
FREMONT, Calif. - Tivic Health Systems, Inc. (Nasdaq: TIVC), a micro-cap bioelectronic therapeutics company with a market capitalization of $2.77 million, has announced new data supporting the development of non-invasive vagus nerve stimulation (ncVNS) devices for treating inflammatory, cardiac, and neurologic disorders. According to InvestingPro analysis, the company maintains a "Fair" overall financial health score, though it faces significant development-stage challenges. The findings, which suggest that personalized ncVNS could be more effective than current treatment options, were presented at the Sixth Bioelectronic Medicine Summit on March 4 & 5.
The research, conducted in collaboration with The Feinstein Institute of Medicine, indicates that no single stimulation frequency universally affects heart rate variability (HRV), a measure of autonomic nervous system activity. While the company’s research progresses, InvestingPro data shows annual revenue of $960,000 with analysts projecting sales growth of 3.16% for the current year. The company maintains a healthy current ratio of 5.65, indicating strong short-term liquidity. Personalizing the ncVNS stimulation frequency for each individual led to a significant increase in HRV, implying enhanced parasympathetic activity and autonomic balance. In 60% of study participants, raw HRV nearly doubled following ncVNS stimulation.
Jennifer Ernst, CEO of Tivic Health, stated that these results validate the company’s approach to creating personalized bioelectronic devices as alternatives to invasive surgeries or pharmaceuticals, which often come with burdensome side effects.
Tivic Health’s poster presentation at the summit highlighted the potential of their novel ncVNS method to modulate autonomic nervous system function and brain activity. The collaboration with the Feinstein Institute aims to advance precision in vagus nerve stimulation with a non-invasive device.
The Bioelectronic Medicine Summit is a key conference where industry leaders, researchers, and clinicians discuss neurotechnologies and neuromodulation therapies. The Feinstein Institutes for Medical Research, known for its work in autonomic neuroscience and inflammation research, hosts the event.
Tivic Health, besides its bioelectronic division, has a biopharma division developing Entolimod™, a TLR5 agonist for treating acute radiation syndrome, which has received Fast Track and Orphan Drug designation from the FDA.
The company already markets an FDA-approved over-the-counter device, ClearUP™, for sinus pain and pressure relief, available through online retailers and commercial distributors.
The press release also includes forward-looking statements, subject to risks and uncertainties, and cautions that actual results could differ materially from those projected. It highlights the company’s reliance on its relationship with the Feinstein Institute, the development of its ncVNS treatment, and its financial needs and Nasdaq listing maintenance. InvestingPro analysis indicates the company is currently holding more cash than debt, though it’s quickly burning through available resources. Based on InvestingPro’s Fair Value analysis, the stock appears to be undervalued at current levels. Subscribers can access 13 additional ProTips and comprehensive financial metrics to better evaluate the investment opportunity.
This news article is based on a press release statement from Tivic Health Systems, Inc.
In other recent news, Tivic Health Systems, Inc. has enacted a 1-for-17 reverse stock split to meet Nasdaq’s minimum bid price requirement, effective March 7, 2025. This strategic move, approved by shareholders, aims to consolidate shares and adjust conversion prices of preferred stock and other equity instruments without altering the total number of authorized shares. Additionally, Tivic Health has filed a new patent application for a personalized vagus nerve stimulation device, which could enhance the efficacy of its therapies. The company anticipates potential FDA approval and commercialization of this device. Previously, Tivic Health faced potential delisting from Nasdaq due to non-compliance with listing requirements, prompting the reverse stock split decision. The company has also communicated with shareholders through a letter, emphasizing its commitment to innovative healthcare solutions. The letter includes cautionary statements about forward-looking projections, highlighting the risks and uncertainties involved. These developments reflect Tivic Health’s ongoing efforts to align with regulatory standards and advance its product offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.